P
Palisade Bio, Inc. (PALI)
2.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
2.00
0.00 (0.00%)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
| Name | Position |
|---|---|
| Dr. James Izanec M.D. | VP & Head of Clinical Development |
| Dr. Joerg Heyer Ph.D. | Head of Translational Science & Medicine |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | President & Chief Medical Officer |
| Mr. Adarsh Patel M.B.A., M.S. | Head of Chemistry, Manufacturing & Controls |
| Mr. Daniel J. Larkins | Head of Global Regulatory Affairs |
| Mr. J. D. Finley | CEO, CFO & Director |
| Mr. Ramesh C. Donthamsetty | Head of Corporate Development & Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-03-20 | 10-K | pali-20251231.htm |
| 2025-12-04 | 8-K | form8-k.htm |
| 2025-11-12 | S-8 | forms-8.htm |
| 2025-11-10 | 10-Q | pali-20250930.htm |
| 2025-11-03 | DEFA14A | formdefa14a.htm |
| 2025-10-28 | DEF 14A | formdef14a.htm |
| 2025-10-22 | 8-K | form8-k.htm |
| 2025-10-20 | 8-K | form8-k.htm |
| 2025-10-17 | PRE 14A | formpre14a.htm |
| 2025-10-16 | 8-K | form8-k.htm |
| Mr. Ryker Willie |
| Senior VP of Finance & Corporate Controller |
| Ms. Sharon Skare Ph.D. | Vice President & Global Head of Clinical Operations |